Histatins constitute a group of small, cationic multifunctional proteins present in the saliva of human and some nonhuman primates. The most significant function of histatins may be their anti-fungal activity against Candida albicans and Cryptococcus neoformans. Histatins have been extensively studied at both the protein and gene levels. The structure-function relationship of histatins with respect to their candidacidal activity has also been studied by means of recombinant histatin variants, as well as by chemically synthesized histatin fragments. The mechanism of histatins' action on Candida albicans is not clear, but it appears to be different from that of azole-based anti-fungal drugs which interrupt ergosterol synthesis. During the past 20 years, fungal infections have become more prevalent as a result of the emergence of AIDS, as well as, paradoxically, modern medical advances. The toxicity of current anti-fungal medicine, the emergence of drug-resistant strains, and the availability of only a few types of anti-fungal agents are the major disadvantages of current anti-fungal therapy. Therefore, the importance of the search for new, broad-spectrum anti-fungals with little or no toxicity cannot be overemphasized. The following properties make histatins promising anti-fungal therapeutic agents: (1) They have little or no toxicity; (2) they possess high cidal activities against azole-resistant fungal species and most of the fungal species tested; and (3) their candidacidal activity is similar to that of azole-based antifungals. Current research efforts focus on the development of improved histatins with enhanced cidal activity and stability, and of suitable and effective histatin delivery systems. These and other approaches may help to outpace the growing list of drug-resistant and opportunistic fungi causing life-threatening, disseminating diseases. The histatins with improved protective properties may also be used as components of artificial saliva for patients with salivary dysfunction.
References
1.
Altman-Hamamdzic S., Groseclose C., Ma JX, Hamamdzic D., Vrindavanam NS, Middaugh LD, et al. (1997). Expression of beta-galactosidase in mouse brain: utilization of a novel nonreplicative Sindbis virus vector as a neuronal gene delivery system. Gene Ther4:815-822.
2.
Atkinson JC, Wu AJ (1994). Salivary gland dysfunction: causes, symptoms, treatment. J Am Dent Assoc125:409-416.
3.
Atkinson JC, Yeh C., Oppenheim FG, Bermudez D., Baum BJ, Fox PC (1990). Elevation of salivary antimicrobial proteins following HIV-1 infection. J AIDS3:41-48.
4.
Audus KL, Borchardt RT (1991) Transport of macromolecules across the capillary endothelium. In: Targeted drug delivery. Juliano RL, editor. New York: Springer-Verlag, pp. 43-70.
5.
Azen EA ( 1972). Genetic polymorphism of basic proteins from parotid saliva. Science176:673-674.
6.
Azen EA ( 1973). Properties of salivary basic proteins showing polymorphism. Biochem Genet9:69-86.
7.
Azen EA ( 1978). Genetic protein polymorphisms in human saliva: an interpretive review. Biochem Genet16:79-99.
8.
Azen EA, Maeda N. (1988). Molecular genetics of human salivary proteins and their polymorphisms. Adv Hum Genet17:141-199.
9.
Azen EA, Hellekant G., Sabatini LM, Warner TF (1990). mRNAs for PRPs, statherin, and histatins in von Ebner's gland tissues. J Dent Res69:1724-1730.
10.
Balekjian AY, Longton RW (1973). Histones isolated from human parotid fluid. Biochem Biophys Res Commun50:676-682.
11.
Baum BJ, Bird JL, Millar DB, Longton RW (1976). Studies on histidine-rich polypeptides from human parotid saliva. Arch Biochem Biophys177:427-436.
12.
Baum B.), Bird JL, Longton RW (1977a). Polyacrylamide gel electrophoresis of human salivary histidine-rich polypeptides. J Dent Res56:1115-1118.
13.
Baum BJ, Ellison SA, Levine M.) (1977b). Differential antigenicity of human salivary histidine-rich polypeptides in goats and rabbits. Arch Oral Biol22:457-459.
14.
Bickel U., Yoshikawa T., Landaw EM, Faull KF, Pardridge WM (1993). Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. Proc Natl Acad Sci USA90:2618-2622.
15.
Bobek LA, Tsai H., Levine MJ (1993). Expression of human salivary histatin and cystatin/histatin chimeric cDNAs in Escherichia coli. Crit Rev Oral Biol Med4:581-590.
16.
Bonilla CA (1969). Rapid isolation of basic proteins and polypeptides from salivary gland secretions by chromatography on polyacrylamide gel. Anal Biochem32:522-529.
17.
Brant EC, Santarpia RP III, Pollock JJ (1990). The role of pH in salivary histidine-rich polypeptide anti-fungal germ tube inhibitory activity. Oral Microbiol Immunol5:336-339.
18.
Budtz-Jorgensen E. (1974). The significance of Candida albicans in denture sore mouth. Scand J Dent Res82:151-190.
19.
Budtz-Jørgensen E. (1990). Candida-associated denture stomatitis and angular cheilitis. In: Oral candidosis. Samaranayake LP, MacFarlane TW, editors. London: Butterworth, pp. 156-183.
20.
Cannon RD, Holmes AR, Mason AB, Monk BC ( 1995). Oral candida: clearance, colonization, or candidiasis? I Dent Res74:1152-1161.
21.
Colon JO, Xu T., Oppenheim FG (1993). Bactericidal effect of salivary histatin-5 on Porphyromonas gingivalis (abstract). J Dent Res72(Spec Iss):322.
22.
Connelly S., Gardner )M., McClelland A., Kaleko M. (1996). High-level tissue-specific expression of functional human factor VIII in mice. Hum Gene Ther7:183-195.
23.
Dickinson DP, Ridall AL, Levine MJ (1987). Human submandibular gland statherin and basic histidine-rich peptide are encoded by highly abundant mRNAs derived from a common ancestral sequence. Biochem Biophys Res Commun149:784-790.
24.
Driscoll J., Zuo Y., Xu T., Choi JR, Troxler RF, Oppenheim FG (1995). Functional comparison of native and recombinant human salivary histatin 1. J Dent Res74:1837-1844.
25.
Driscoll J., Duan C., Zuo Y., Xu T., Troxler R., Oppenheim FG (1996a). Candidacidal activity of human salivary histatin recombinant variants produced by site-directed mutagenesis. Gene177:29-34.
26.
Driscoll J., Zuo Y., Xu T., Troxler RF, Oppenheim FG (1996b). Investigation of the anti-candidal mechanism of histatins (abstract). J Dent Res75(Spec Iss):358.
27.
Driscoll J., Xu T., Oppenheim FG (1997). Histatins: structure, function, and genetics. In: Studies in stomatology and craniofacial biology. Cohen MM, Baum BJ. editors. Amsterdam, The Netherlands: IOS Press, pp. 445-460.
28.
Edgerton M., Lo SE, Levine M.j (1993). Histatins induce leakage from C. albicans cells and model liposome membrane (abstract). J Dent Res72(Spec Iss):322.
29.
Edgerton M., Raj PA, Levine MJ (1995). Surface-modified poly(methyl methacrylate) enhances adsorption and retains anti-candidal activities of salivary histatin 5. J Biomed Mater Res29:1277-1286.
30.
Edgerton M., Lo T., Raj PA (1996). Salivary histatin-3 and histatin-5 exhibit specific binding to yeast cell membranes (abstract). J Dent Res75(Spec Iss):358.
31.
Epstein JB, Freilich MM, Le ND (1993). Risk factors for oropharyngeal candidiasis in patients who receive radiation therapy for malignant conditions of the head and neck. Oral Surg Oral Med Oral Pathol76:169-174.
32.
Garg AK, Malo M. ( 1997). Manifestation and treatment of xerostomia and associated oral effects secondary to head and neck radiation therapy. J Am Dent Assoc128:1128-1133.
Hawkins C., Armstrong D. (1984). Fungal infections in the immunocompromised host. Clin Haematol13:599-630.
35.
Hay D.l (1975). Fractionation of human parotid salivary proteins and the isolation of an histidine-rich acidic peptide which shows high affinity for hydroxyapatite surfaces. Arch Oral Biol20:553-558.
36.
Holbrook IB, Molan PC (1975). The identification of a peptide in human parotid saliva particularly active in enhancing the glycolytic activity of the salivary microorganisms. Biochem J149:489-492.
37.
Jensen JL, Xu T., Lamkin MS, Brodin P., Aars H., Berg T., et al. (1994). Physiological regulation of the secretion of histatins and statherins in human parotid saliva. J Dent Res73:1811-1817.
38.
Joly V., Bolard J., Yeni P. ( 1992). In vitro models for studying toxicity of anti-fungal agents. Antimicrob Agent Chemother36:1799-1804.
39.
Kagami H., O'Connell BC, Baum BJ ( 1996). Evidence for the systemic delivery of a transgene product from salivary glands. Hum Gene Ther7:2177-2184.
40.
Kalpidis CD, Xu T., Oppenheim FG (1992). Effects of human salivary histatin-5 on Actinomyces species (abstract). J Dent Res71 (Spec Iss):305.
41.
Kalpidis CD, Xu T., Murakami Y., Oppenheim FG (1995). Inhibition of Bacteroides forsythus hemagglutination by human salivary histatins (abstract). J Dent Res74(Spec Iss):123.
42.
Kato T., Takahashi N., Kuramitsu H. (1992). Sequence analysis and characterization of the Porphyromonas gingivalis prtC gene, which expresses a novel collagenase activity. J Bacteriol174:3889-3895.
43.
Koshlukova S., Lo T., Chrzan B., Edgerton M. (1997). Histatin interaction with Candida albicans envelope protein is related to candidacidal activity (abstract). ] Dent Res76(Spec Iss):296.
44.
Lachmann RH, Efstathiou S. (1997). The use of herpes simplex virus-based vectors for gene delivery to the nervous system. Mol Med Today3:404-411.
45.
Lal K., Pollock JJ, Santarpia RP 111, Heller HM, Kaufman HW, Fuhrer J., et al. (1992a). Pilot study comparing the salivary cationic protein concentration in healthy adults and AIDS patients: correlation with anti-fungal activity. I Acquir Immune Defic Syndr5:904-914.
46.
Lal K., Santarpia RP III, Xu L., Manssuri F., Pollock JJ (1992b). One-step purification of histidine-rich polypeptides from human parotid saliva and determination of anti-candidal activity. Oral Microbiol Immunol7:44-50.
47.
Lal K., Xu L., Colburn J., Hong AL, Pollock JJ (1992c). The use of capillary electrophoresis to identify cationic proteins in human parotid saliva. Arch Oral Biol37:7-13.
48.
Lamkin MS, Oppenheim FG (1993). Structural features of salivary function. Crit Rev Oral Biol Med4:251-259.
49.
MacKay BJ, Pollock JJ, lacono VJ, Baum BJ (1984a). Isolation of milligram quantities of a group of histidine-rich polypeptides from human parotid saliva. Infect Immun44:688-694.
50.
MacKay BJ, Denepitiya L., lacono VI, Krost SB, Pollock JJ (1984b). Growth-inhibitory and bactericidal effects of human parotid salivary histidine-rich polypeptides on Streptococcus mutans. Infect Immun44:695-701.
51.
Mandel ID Barr CE, Turgeon L. (1992). Longitudinal study of parotid saliva in HIV-1 infection. I Oral Pathol Med21:209-213.
52.
Mitchell TG, Perfect JR (1995). Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev8:515-548.
53.
Murakami Y., Takeshita T., Shizukuishi S., Tsunemitsu A., Aimoto S. (1990). Inhibitory effects of synthetic histidine-rich peptides on haemagglutination by Bacteroides gingivalis 381. Arch Oral Biol35:775-777.
54.
Murakami Y., Nagata H., Amano A., Takagaki M., Shizukuishi S., Tsunemitsu A., et al. (1991a). Inhibitory effects of human salivary histatins and lysozyme on coaggregation between Porphyromonas gingivalis and Streptococcus mitis. Infect lmmun59:3284-3286.
55.
Murakami Y., Shizukuishi S., Tsunemitsu A., Nakashima K., Kato Y., Aimoto S. (1991b). Binding of a histidine-rich peptide to Porphyromonas gingivalis. FEMS Microbiol Lett82:253-256.
56.
Murakami Y., Nagata H., Shizukuishi S., Nakashima K., Okawa T., Takigawa M., et al. ( 1994). Histatin as a synergistic stimulator with epidermal growth factor of rabbit chondrocyte proliferation. Biochem Biophus Res Commun198:274-280.
57.
Murakami Y., Xu T., Oppenheim FG (1995). Inhibitory effect of histatin-5 on leukotoxin from Actinobacillus actinomycetemcomitans (abstract). J Dent Res74(Spec Iss):123.
58.
Naffakh N., Pinset C., Montarras D., Li S., Paulin D., Danos O., et al. (1996). Long-term secretion of therapeutic proteins from genetically modified skeletal muscles. Hum Gene Ther7:11-21.
59.
Nishikata M., Kanehira T., Oh H., Tani H., Tazaki M., Kubo Y. ( 1991). ). Salivary histatin as an inhibitor of a protease produced by the oral bacterium Bacteroides gingivalis. Biochem Biophys Res Commun174:625-630.
60.
O'Connell BC, Baum B.) (1997). Gene transfer to salivary glands. In: Studies in stomatology and craniofacial biology. Cohen MM, Baum BJ, editors. Amsterdam, The Netherlands: IOS Press, pp. 615-631.
61.
O'Connell BC, Xu T., Walsh TJ, Sein T., Mastrangeli A., Crystal RG, et al. (1996). Transfer of a gene encoding the anti-candidal protein histatin 3 to salivary glands. Hum Gene Ther7:2255-2261.
62.
Odds FC ( 1988). Candida and candidosis: a review and bibliography. 2nd ed. London, UK: Bailliere Tindall.
63.
Oppenheim FG, Yang YC, Diamond RD, Hyslop D., Offner GD, Troxler RF (1986). The primary structure and functional characterization of the neutral histidine-rich polypeptide from human parotid secretion. J Biol Chem261:1177-1182.
64.
Oppenheim FG, Xu T., McMillian FM, Levitz SM, Diamond RD, Offner GD, et al. (1988). Histatins, a novel family of histidine-rich proteins in human parotid secretion. J Biol Chem263:7472-7477.
65.
Palmer TD, Thompson AR, Miller AD (1989). Production of human factor IX in animals by genetically modified skin fibroblasts: potential therapy for hemophilia B. Blood73:438-445.
66.
Pals G., Pronk JC (1979). Genetic variation in parotid basic proteins (Pb) in the Bozo (Mali, West Africa). Hum Genet49:355-359.
67.
Pannuti CS, Gingrich R., Pfaller MA, Kao C., Wenzel RP (1992). Nosocomial pneumonia in patients having bone marrow transplant. Cancer69:2653-2662.
68.
Paquette DW, Waters GS, Stefanidou VL, Lawrence HP, Friden PM, O'Connor SM, et al. (1997). Inhibition of experimental gingivitis in beagle dogs with topical salivary histatins. J Clin Periodontol24:216-222.
69.
Parvinen T., Larmas M. (1981). The relation of stimulated salivary flow rate and pH to lactobacillus and yeast concentrations in saliva. J Dent Res60:1929-1935.
70.
Payne JB, lacono VJ, Crawford IT, Lepre BM, Bernzweig E., Grossbard BL (1991). Selective effects of histidine-rich polypeptides on the aggregation and viability of Streptococcus mutans and Streptococcus sanguis. Oral Microbiol Immunol6:169-176.
71.
Peters EH, Goodfriend T., Azen EA ( 1977). Human Pb, human post-Pb, and nonhuman primate Pb proteins: immunological and biochemical relationships. Biochem Genet15:947-963.
72.
Peterson DE (1992). Oral candidiasis. Clin Geriat Medi8:513-527.
73.
Polak A. (1989). Combinations therapy for systemic mycosis. Infection17:203-209.
74.
Pollock JJ, Denepitiya L., MacKay BJ, lacono VJ (1984). Fungistatic and fungicidal activity of human parotid salivary histidine-rich polypeptides on Candida albicans. Infect Immun44:702-707.
75.
Pronk JC, lansen WJ, Pronk A., vdPol Cfam, Frants RR, Eriksson AW (1984). Salivary protein polymorphism in Kenya: evidence for a new AMY1 allele. Hum Hered34:212-216.
76.
Raj PA, Edgerton M., Levine MJ (1990). Salivary histatin-5: dependence of sequence, chain length, and helical conformation for candidacidal activity. J Biol Chem265:3898-3905.
77.
Raj PA, Soni SD, Levine MJ (1994). Membrane-induced helical conformation of an active candidacidal fragment of salivary histatins. J Biol Chem269:9610-9619.
78.
Raj PA, Marcus E., Sukumaran DK (1998). Structure of human salivary histatin 5 in aqueous and non-aqueous solutions. Biopolymers45:51-67.
79.
Ramalingam K., Gururaja TL, Ramasubbu N., Levine MJ (1996). Stabilization of helix by side-chain interactions in histatin-derived peptides: role in candidacidal activity. Biochem Biophys Res Commun225:47-53.
80.
Rayhan R., Xu L., Santarpia RP III, Tylenda CA, Pollock JJ (1992). Anti-fungal activities of salivary histidine-rich polypeptides against Candida albicans and other oral yeast isolates. Oral Microbiol Immunol7:51-52.
81.
Robinson DH, Mauger JW (1991). Drug delivery systems. Am J Hosp Pharm48:S14-S23.
82.
Rosenfeld MA, Siegfried W., Yoshimura K., Yoneyama K., Fukuyama M., Stier LE, et al. (1991). Adenovirus-mediated transfer of a recombinant α1-antitrypsin gene to the lung epithelium in vivo. Science252:431-434.
83.
Sabatini LM, Azen EA ( 1989). Histatins, a family of salivary histidine-rich proteins, are encoded by at least two loci (HIS1 and HIS2). Biochem Biophys Res Commun160:495-502.
84.
Sabatini LM, Azen EA ( 1994). Two coding change mutations in the HIS22 allele characterize the salivary histatin 3-2 protein variant. Hum Mutat4:12-19.
85.
Sabatini LM, Warner TF, Saitoh E., Azen EA ( 1989). Tissue distribution of RNAs for cystatins, histatins, statherin, and proline-rich salivary proteins in humans and Macaques. J Dent Res68:1138-1145.
86.
Sabatini LM, Ota T., Azen EA ( 1993). Nucleotide sequence analysis of the human salivary protein genes HIS1 and HIS2, and evolution of the STATH/HIS gene family. Mol Biol Evol10:497-511.
87.
Saito Y., Buciak J., Yang J., Pardridge WM (1995). Vector-mediated delivery of 125I-labeled β-amyloid peptide Aβ1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the Aβ1-40/vector complex. Proc Natl Acad Sci USA92:10227-10231.
88.
Samaranayake LP, McCourtie J., MacFarlane TW (1980). Factors affecting the in vitro adherence of Candida albicans to acrylic surfaces. Arch Oral Biol25:611-615.
89.
Santarpia RP III, Brant EC, Lal K., Brasseur MM, Hong AL, Pollock JJ (1988). A comparison of the inhibition of blastospore viability and germ-tube development in Candida albicans by histidine peptides and ketoconazole. Arch Oral Biol33:567-573.
90.
Santarpia RP III, Cho MI, Pollock JJ (1990). Parameters affecting the inhibition of Candida albicans GDH2023 and GR12773 blastospore viability by purified synthetic salivary histidine-rich polypeptides. Oral Microbiol Immunol5:226-232.
91.
Santarpia RP III, Pollock JJ, Renner RP, Gwinnett AJ (1991). In vivo anti-fungal efficacy of salivary histidine-rich polypeptides: preliminary finding in a denture stomatitis model system. J Prosthet Dent66:693-699.
92.
Sayani AP, Chien YW (1996). System delivery of peptides and proteins across absorptive mucosae. Crit Rev Ther Drug Carrier Sys13:85-184.
93.
Shrestha P., Hashimoto J., Takagi H., Yamada K., Mori M., Kanehira T., et al. (1994). lmmunoreactive histatin 5 in salivary gland tumors. Acta Histochem Cytochem27:527-534.
94.
Smith DB, Johnson KS (1988). Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene67:31-40.
95.
Sternberg S. (1994). The emerging fungal threat. Science266:1632-1634.
96.
Suddick RP, Hyde RJ, Feller RP (1980). Salivary water and electrolytes and oral health. In: The biological basis of dental caries, an oral biology textbook. Menaker L, editor. Hagerstown, MD: Harper & Row Publishers, Inc., pp. 132-147.
97.
Sugiyama K. (1993). Anti-lipopolysaccharide activity of histatins, peptides from human saliva. Experientia49:1095-1097.
98.
Sugiyama K., Ogata K. (1993). High-performance liquid chromatographic determination of histatins in human saliva. J Chromatogr619:306-309.
99.
Sugiyama K., Suzuki Y., Furuta H. (1985). Isolation and characterization of histamine-releasing peptides from human parotid saliva. Life Sci37:475-480.
100.
Troxler RF, Öffner GD, Xu T., VanderSpek JC, Oppenheim FG (1990). Structural relationship between human salivary histatins. J Dent Res69:2-6.
101.
Tsai H. ( 1997). Structure-function studies of human salivary histatins with respect to their candidacidal activity (dissertation). Buffalo, NY: State Univ. of New York.
102.
Tsai H., Bobek LA (1997a). Human salivary histatin-5 exerts potent fungicidal activity against Cryptococcus neoformans (rapid report). Biochim Biophys Acta1336:367-369.
103.
Tsai H., Bobek LA (1997b). Studies on the mechanism of human salivary histatin-5 cidal activity using histatin-5 variants and azole-sensitive and -resistant Candida species. Antimicrob Agents Chemother41:2224-2228.
104.
Tsai H., Raj PA, Bobek LA (1996). Candidacidal activity of recombinant human salivary histatin-5 and variants. Infect Immun64:5000-5007.
105.
Tsai H., Raj PA, Bobek LA (1997). Candidacidal activity and helical conformation of active C-terminal fragments of human salivary histatin-5. Int J Oral Biol22:67-71.
106.
Tsuchida S., Ikemoto S. (1989). Further studies of salivary polymorphisms in the Japanese population. Hum Hered39:61-66.
107.
Vanden Bossche H., Willemsens G., Marichal P. (1987). Anti-candida drugs-The biochemical basis for their activity. CRC Crit Rev Microbiol15:57-72.
108.
Vanden Bossche H., Warnock DW, Dupont B., Kerridge D., Sen Gupta S., lmprovisi L., et al. (1994). Mechanisms and clinical impact of anti-fungal drug resistance. J Med Vet Mycol32(Suppl 1): 189-202.
109.
VanderSpek JC, Wyandt HE, Skare )C, Milunsky A, Oppenheim FG, Troxler RF (1989). Localization of the genes for histatins to human chromosome 4ql3 and tissue distribution of the mRNA. Am J Hum Genet45:381-387.
110.
VanderSpek JC, Öffner GD, Troxler RF, Oppenheim FG (1990). Molecular cloning of human submandibular histatins. Arch Oral Biol35:137-143.
111.
Xu L., Lal K., Pollock JJ (1992). Histatins 2 and 4 are auto-proteolytic degradation products of human parotid saliva. Oral Microbiol Immunol7:127-128.
112.
Xu L., Lal K., Santarpia RP III, Pollock JJ (1993). Salivary proteolysis of histidine-rich polypeptides and the anti-fungal activity of peptide degradation products. Arch Oral Biol38:277-283.
113.
Xu T., Oppenheim FG (1993). Salivary antimicrobials: where are we? Ann NY Acad Sci694:117-131.
114.
Xu T., Levitz SM, Diamond RD, Oppenheim FG (1991). Anti-candidal activity of major human salivary histatins. Infect lmmun59:2549-2554.
115.
Xu T., Kalpidis CD, Oppenheim FG (1995). Effects of human salivary histatins on Streptococcus rattus glycolysis (abstract). J Dent Res74(Spec Iss):122.
116.
Yan Q., Bennick A. (1995). Identification of histatins as tannin-binding proteins in human saliva. Biochem J311:341-347.
117.
Zegarelli EV, Kutscher AH, Herlands RE, Lucca JJ, Silvers HF (1961). Oral lesions of interest to the prosthodontist. Part I, denture stomatitis. J Prosthet Dent11:617-620.
